Cardiac aldosterone overexpression prevents harmful effects of diabetes in the mouse heart by preserving capillary density
- 2 March 2009
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 23 (7) , 2176-2185
Abstract
Recent reports showed an unexpected worsening of endothelial function by aldosterone antagonism in diabetic patients, suggesting that aldosterone could interfere with the detrimental consequences of diabetes on microvasculature and thus on cardiac function. To test this hypothesis, diabetes (D) was induced using streptozotocin in transgenic (Tg) male mice overexpressing aldosterone‐synthase in the heart and in wild‐type (Wt) mice. Eight weeks after streptozotocin injection, impairment of left ventricular systolic function, measured by echocardiography (fractional shortening), was accompanied by a decrease in capillaries/cardiomyocyte ratio (—20%) and VEGFa expression (—40%) in Wt‐D mice compared with normoglycemic littermates. Furthermore, Wt‐D mice demonstrated an increase in superoxide production (+100%) and protein carbonylation (+33%), hallmarks of oxidative stress. Except for a slight increase in protein carbonylation, all of these diabetes‐associated cardiac alterations were undetectable in Tg‐D mice. Fibrosis was induced similarly in both diabetic groups. Eplerenone (an aldosterone antagonist) abolished all of the effects of aldosterone‐synthase overexpression but had no effect in Wt‐D mice. Thus, aldosterone prevents systolic dysfunction through a mineralocorticoid receptor‐dependent mechanism that may include preventing VEGFa down‐regulation and maintaining capillary density. Understanding how aldosterone prevents VEGFa down‐regulation in experimental diabetes could be important to define new strategies targeting the prevention of a decrease in capillary density.—Messaoudi, S.,Milliez, P., Samuel, J.‐L., Delcayre, C. Cardiac aldosterone overexpression prevents harmful effects of diabetes in the mouse heart by preserving capillary density. FASEB J. 23, 2176–2185 (2009)Keywords
This publication has 47 references indexed in Scilit:
- A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosisAmerican Heart Journal, 2008
- Aldosterone upregulates vascular endothelial growth factor expression in mouse cortical collecting duct epithelial cells through classic mineralocorticoid receptorLife Sciences, 2007
- Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetesLife Sciences, 2006
- Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Failure in Low-Aldosterone Hypertensive RatsHypertension, 2006
- Effects of Aldosterone on the VasculatureHypertension, 2006
- Working heart function in diabetes is not improved by spironolactone treatmentCanadian Journal of Physiology and Pharmacology, 2003
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphologyCardiovascular Research, 1993
- Rise of Plasma Aldosterone during Long-Term Captopril TreatmentNew England Journal of Medicine, 1981
- New type of cardiomyopathy associated with diabetic glomerulosclerosisThe American Journal of Cardiology, 1972